key: cord-0795273-ktgwdxs9
authors: Szolnoky, Győző
title: Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID‐19 induced vascular complications
date: 2020-11-02
journal: Dermatol Ther
DOI: 10.1111/dth.14437
sha: 49e0277ae9cc57d0d189305c2f1c066a98c34ec0
doc_id: 795273
cord_uid: ktgwdxs9

nan

Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications Dear Editor, In their work Demirbaş et al presented a patient with COVID-19-associated superficial thrombophlebitis successfully treated with enoxaparine, 1 a low molecular weight heparin (LMWH) medication and also gave a brief, but detailed overview on SARS-Cov-2 induced coagulopathy and the intensive cross-talk between immune system and hemostasis. 1 Besides the frequently quoted acute respiratory distress syndrome and dysregulation of coagulation and fibrinolytic systems, COVID-19 infection is often associated with complement activation, 1 hypoxaemia, 1 higher blood viscosity, 2 inflammatory endothelial damage (endotheliitis), 3 (HIT) and occasionally major bleeding. 5 By contrast, theraputic dosages may induce resistance to UHF or LMWH in a certain subset of SARS-CoV-2 infected patients. 5 Danaparoid is a blend of heparan sulfate, dermatan sulfate and chondroitin sulfate and would seem theoretically a candidate against COVID-19-associated vasculo-and coagulopathies but has never been tested extensively for this purpose. 6 According to in vitro studies direct oral anticoagulant medications (DOACs) would represent a predictable effect in COVID-19 however clinical studies have only partially confirmed this theory. 6 The expensive parenteral anticoagulant fondaparinux does not cause HIT however its utility in COVID-19 infection is still under investigation. 6 The application of vitamin-K antagonists is associated with numerous limitations such as the need of routine coagulation monitoring and interactions with food and medications. 6 Sulodexide (SDX) is a natural glycosaminoglycane composed of 80% fast moving heparin (FMH) plus 20% dermatan sulfate and its in vitro antihemostatic effects are at least comparable with those of enoxaparine. 7 Biological activity comprises arterial and venous antithrombotic and profibrinolytic (increased tissue plasminogen activator level, inhibition of platelet aggregation), antiinflammatory (eg, suppressed interleukin-6 production) and beneficial hemorheologic (lipid profile modification) effects. 7 SDX protects and repairs endothelial layer by glycocalyx restoration and vascular tone regulation, 7,8 displays senolytic activity, 9 and attenuates ischemia-reperfusion injury. 7 Compared with LMWHs it is less likely associated with bleeding risk, much weaker in HIT and renal insufficiency does not demand dose reduction. 7 In COVID-19 infection the pleiotropic SDX may represent an alternative to LMWH as a prophylactic agent. Unlike other heparins, SDX can be administered orally with sufficient intestinal absorption providing a median bioavailability of appoximately 40% which also eliminates the fear of needles of LMWH injections. It is safe to use in renal insufficiency and less likely related to HIT, major bleeding and drug-induced hypersensitivity compared with LMWHs. 7 

Superficial thrombophlebitis in a patient with COVID 19: heparin treatment after evaluation of D-dimer

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

Endothelial cell infection and endotheliitis in COVID-19

The liaison between respiratory failure and high blood pressure

Heparin failure and COVID-19: should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care

Pharmacological agents targeting Thromboinflammation in COVID-19: review and implications for future research

Development and use of sulodexide in vascular diseases: implications for treatment

Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway

Sulodexide slows down the senescence of aortic endothelial cells exposed to serum from patients with peripheral artery diseases